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Plasmacytoid dendritic cells (pDCs) are a particular subset of DCs that link innate and
adaptive immunity.They are responsible for the substantial production of type 1 interferon
(IFN-I) in response to viral RNA or DNA through activation ofTLR7 and 9. Furthermore, pDCs
present antigens (Ag) and induce naïveT cell differentiation. It has been demonstrated that
pDCs can induce immunogenic T cell responses through differentiation of cytotoxic CD8+
T cells and effector CD4+ T cells. Conversely, pDCs exhibit strong tolerogenic functions by
inducing CD8+ T cell deletion, CD4+ T cell anergy, and Treg differentiation. However, since
IFN-I produced by pDCs efficiently activates and recruits conventional DCs, B cells,T cells,
and NK cells, pDCs also indirectly affect the nature and the amplitude of adaptive immune
responses. As a consequence, the precise role of Ag-presenting functions of pDCs in
adaptive immunity has been difficult to dissect in vivo. Additionally, different experimental
procedures led to conflicting results regarding the outcome of T cell responses induced
by pDCs. During the development of autoimmunity, pDCs have been shown to play both
immunogenic and tolerogenic functions depending on disease, disease progression, and
the experimental conditions. In this review, we will discuss the relative contribution of
innate and adaptive pDC functions in modulating T cell responses, particularly during the
development of autoimmunity.
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PLASMACYTOID DENDRITIC CELL CHARACTERISTICS
Plasmacytoid dendritic cells (pDCs) were first described as either
interferon (IFN) producing cells (Ronnblom et al., 1983; Chehimi
et al., 1989; Fitzgerald-Bocarsly, 1993) or as plasmacytoid mono-
cytes or plasmacytoid T cells in reference to their plasma-like
morphology in secondary lymphoid organs (SLOs) (Facchetti
et al., 1988). They were further defined as pre-DC2, as during acti-
vation they can differentiate into conventional DCs (cDCs)-like
cells. These cells exhibit a DC morphology, with increased MHC
class II (MHCII) and costimulatory molecule expression, and the
ability to induce naïve CD4+ T cell proliferation (Grouard et al.,
1997). In 1999, the groups of M. Colonna and Y. J. Liu formally
demonstrated that all these cell subtypes were actually the same
entity, the pDCs (Cella et al., 1999; Siegal et al., 1999).
The development of pDCs occurs in the bone marrow (BM),
after which they circulate through the blood stream, and reside
in steady-state in the thymus and in the SLOs. Upon challenge
via infection or inflammation, pDCs migrate and accumulate in
inflamed tissues and draining lymph nodes (dLNs) (Reizis et al.,
2011). The pDCs derive from the common dendritic progeni-
tors (CDP) which express FLT3-R (CD135), CSF1-R (CD115),
and low levels of c-kit (CD117) (Onai et al., 2007). Alterna-
tively, pDCs may derive from lymphoid progenitors (Shigematsu
et al., 2004; Luo and Lei, 2012; Sathe et al., 2013). Differentiation
of pDCs relies essentially on Flt3-L which allows the expansion
of cDC/pDC common progenitors and contributes to periph-
eral DC homeostasis (Waskow et al., 2008; Eidenschenk et al.,
2010). The importance of E2-2 has been demonstrated for pDC
differentiation (Cisse et al., 2008). It was further described that
E2-2 drives the expression of other transcription factors involved
in pDC fate, such as IRF-8 or Spi-B, while it inhibits other factors
that are important for cDC differentiation, including Id-2 (Ghosh
et al., 2010). Thus, a balance between the transcription factors
E2-2 and Id-2 appears to control the differentiation toward the
pDC lineage. Accordingly, in E2-2 deficient mice, pDCs exhibit an
increased expression of Id-2 that correlates with a conversion into
cDCs.
At the phenotypic level, pDCs are characterized by having inter-
mediate (mouse) or no (human) expression of the DC marker
CD11c. They are positive for the B cell marker CD45RA/B220, and
express high levels of PDCA1, BST-2, Ly6C, and Ly49Q in mouse
and BDCA-2, ILT-7, IL3Ra (CD123), and BDCA-4 in human
(Reizis et al., 2011).
INNATE PLASMACYTOID DC FUNCTIONS
FEATURES OF pDC INNATE FUNCTIONS
Plasmacytoid DCs are strong sensors of non-self nucleic acids
derived from bacteria or viruses through binding to Toll-like
receptors (TLR). Nucleic acids come from either viruses inter-
nalized by endocytosis, cytoplasmic viral RNA by autophagy
(Lee et al., 2007), or other infected cells via exosome transport
(Dreux et al., 2012). The receptors TLR7 and TLR9 are selectively
expressed by pDCs. Interestingly, pDCs are the only DC subset
expressing TLR9 in humans (Jarrossay et al., 2001; Kadowaki et al.,
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2001; Hornung et al., 2002) but not in mice (Chen et al., 2006).
TLR7 senses guanosine or uridine rich single-stranded RNA from
viruses or synthetic compounds such as imidazoquinoline and
guanosine analogs (Diebold et al., 2004; Heil et al., 2004; Lund
et al., 2004), while TLR9 recognizes single-stranded DNA con-
taining unmethylated CpG motifs commonly found in viral and
bacterial genomes (Hemmi et al., 2000; Bauer et al., 2001). The
activation of TLR9 can also be through synthetic oligonucleotides
(ODN) that mimic viral ssDNA responses (Kadowaki et al., 2001).
TLR binding signals through MyD88, an adaptor protein that
forms a signaling scaffold with IRAK-4, TRAF-6, and Btk, and
induces the formation of the TRAF-3/IRAK-1/IKK-α/OPN/PI3K
complex. As a consequence, IRF-7 is phosphorylated and subse-
quently translocated in the nucleus where it induces IFN-I gene
transcription. Signaling through TRAF-6 also induces the NF-κB
and MAPK pathways, leading to the secretion of inflammatory
cytokines and chemokines, and the up-regulation of costimulatory
molecules (Gilliet et al., 2008). Unlike other cells, where expression
is dependent on IFNAR signaling, IRF-7 is constitutively expressed
in pDCs (Honda et al., 2005b; Ito et al., 2006), possibly due to
the low expression of the negative translational repressors 4EBPs
(Colina et al., 2008).
The TLR ligands CpG-ODN have been classified as CpG-A, -
B, and -C based on the different immune responses induced. In
pDCs, CpG-A gives rise to robust IFN-I production, whereas CpG-
B induces the production of inflammatory cytokines such as TNF
or IL-6, as well as the up-regulation of MHCII and costimula-
tory molecules at the pDC surface (Kerkmann et al., 2005). These
distinct effects of CpG-A and -B are pDC-specific and rely on
different intracellular localizations after internalization. CpG-A
possesses a poly-G tail, leading to the formation of a large mul-
timeric complex that is retained in early endosomes and signals
through MyD88 and IRF-7, thus inducing a strong IFN-I response.
Conversely, monomeric CpG-B fails to be retained in early endo-
somes and rapidly travels to late endosomes/lysosomes to induce
TNF and IL-6 production, and costimulatory molecule expression
(Honda et al., 2005a; Guiducci et al., 2006).
Production of IFN-I by pDCs is much stronger (200–1000 times
more effective) than any other cell type (Siegal et al., 1999). Mul-
tiple subtypes of IFN-I are secreted by pDCs, including IFNα,
β, κ, ω, λ, and τ (Ito et al., 2006). During viral infections, pDC
ablation selectively abrogates the early peak of IFN-I and leads
to an increased viral burden (Swiecki et al., 2010), suggesting
that IFN-I secretion is particularly crucial at the beginning of
the antiviral response. By itself, IFN-I promotes the expression of
IFN-stimulated genes that inhibit viral spreading through different
mechanisms: (i) inhibition of viral replication by RNA degrada-
tion (Malathi et al., 2005) or by decreased protein synthesis (Barber
et al., 1993); (ii) establishment of an antiviral state in uninfected
cells; and (iii) induction of infected cell apoptosis (Pestka et al.,
2004). Importantly, IFN-I links innate and adaptive immunity as it
induces the differentiation, maturation, and activation of myeloid
DCs that in turn promote antiviral T cell immunity (Paquette
et al., 1998; Santini et al., 2000; Hibbert et al., 2003; Le Bon et al.,
2003; Fonteneau et al., 2004; Yoneyama et al., 2005). Furthermore,
IFN-I activates the antiviral functions of NK cells (Gerosa et al.,
2005) and B cells (Jego et al., 2003). Using conditional targeting of
the pDC-specific transcription factor E2-2, an elegant study has
shown that pDC-deficient mice fail to clear chronic LCMV infec-
tion (Cervantes-Barragan et al., 2012). This defect correlates with
impaired LCMV-specific CD4+ and CD8+ T cell numbers and
functions, and relies on the lack of IFN-I production by pDCs,
independently of their antigen (Ag) presenting capabilities.
INNATE pDC FUNCTIONS AND AUTOIMMUNITY
Self-DNA has been demonstrated to activate pDCs in autoimmune
diseases. Under normal conditions, self-DNA is not recognized by
pDCs since, when released by necrotic and apoptotic cells (Pisetsky
and Fairhurst, 2007), it remains in the extracellular environment
(Barton et al., 2006) and is rapidly degraded by DNAses. Following
skin injury in psoriasis, self-DNA is released in the extracellular
milieu (Lande et al., 2007) and sensed by pDCs (Nestle et al., 2005).
In the wounded skin, the cationic anti-microbial cathelicidin LL37
is produced by keratinocytes and neutrophils (Zasloff, 2002). LL37
production is increased in psoriatic skin, binds the DNA released
by dying cells, and forms aggregates which are resistant to extracel-
lular nucleases (Lande et al., 2007). These complexes enter pDCs
by endocytosis via lipid rafts and interactions with proteoglycans
(Sandgren et al., 2004), and localize in early endosomes (similarly
to CpG-A) to induce a strong IFN-I response. Consistently, an
Imiquimod (TLR7 ligand)-containing topical cream was shown
to exacerbate psoriatic lesions (Gilliet et al., 2004).
It has also been shown that IFN-I also plays a major role in the
development of systemic lupus erythematosus (SLE) (Chan et al.,
2012), by inducing the differentiation of both auto-antibody pro-
ducing plasma cells (Jego et al., 2003; Thibault et al., 2009; Mathian
et al., 2011) and cDC-driven effector T cells (Blanco et al., 2001). In
SLE, apoptotic and necrotic cell derived self-DNA are complexed
with (i) the peptide LL37, released by apoptotic neutrophil extra-
cellular traps (NETs) in skin lesions (Bennett et al., 2003; Garcia-
Romo et al., 2011; Lande et al., 2011), (ii) the protein HMGB1,
also released in NETs, which binds aggregated nucleic acids (like
CpG-A) (Tian et al., 2007), and (iii) by auto-antibodies directed
against nucleic acids or nucleoproteins (Lovgren et al., 2004).
These immune complexes allow the delivery of self-DNA into
pDCs through the interaction of auto-Ab with FcγRII (CD32),
and LC3-associated phagocytosis, a process described as a con-
vergence between phagocytosis and non-conventional autophagy
(Henault et al., 2012). In endosomes, self-DNA activates TLR sig-
naling and subsequent IFN-I production (Lovgren et al., 2004;
Barrat et al., 2005). Moreover, HMGB1 interacts with RAGE at the
pDC surface, facilitating TLR9/DNA-binding in endosomes with-
out inducing endocytosis (Tian et al., 2007). Finally, the resulting
robust production of IFN-I, together with the presence of anti-
LL37 auto-Abs in sera of SLE patients, induces the release of NETs
and the continuous release of immune complexes (Garcia-Romo
et al., 2011; Lande et al., 2011).
In multiple sclerosis (MS), many studies have suggested a
protective role of pDCs and IFN-I. Indeed, relapsing patients
treated with IFNβ-1a exhibit both a reduction in disease sever-
ity and a delay in relapses (Goodkin, 1996). In experimental
autoimmune encephalomyelitis (EAE), a deficiency of IFNAR
in central nervous system (CNS) myeloid cells exacerbates dis-
ease development (Prinz et al., 2008). In addition, pDCs have
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been shown to inhibit cDC functions and, consequently, dampen
the development of encephalitogenic Th17 cells (Bailey et al.,
2007), whereas anti-PDCA1 mediated pDC depletion increases
EAE severity (Bailey-Bucktrout et al., 2008). As discussed by the
authors, and consistent with the IFN-I dependent inhibition of
Th17 inflammation in the CNS (Guo et al., 2008), pDC-mediated
protection may indeed depend on IFN-I. However, the molecular
mechanisms accounting for the local suppression of pathogenic T
cells in the CNS by pro-inflammatory IFN-I remain unclear.
Until recently, the contribution of pDCs and IFN-I to patho-
genesis in type 1 diabetes (T1D) remained controversial. The role
of IFN-I, first believed to be protective (Sobel and Ahvazi, 1998;
Sobel et al., 1998; Tanaka-Kataoka et al., 1999; Brod, 2002) has been
revisited as IFN-I expression in insulin-producing β cells exacer-
bates T1D progression (Stewart et al., 1993; Alba et al., 2004).
Furthermore, whereas pDCs were demonstrated to secrete IFN-I
in dLNs from 3-week-old Non-Obese Diabetic (NOD) mice, pDC
depletion in this strain dampened IFN-I production and diabetes
progression. This protective effect is seemingly IFN-I dependent,
since IFNAR blockade equally delayed diabetes onset (Li et al.,
2008). Finally, Diana et al. recently formally demonstrated that
IFN-α-producing pDCs are required for the initiation of diabeto-
genic T cell responses and T1D development. The study found
that spontaneous β-cell death in young NOD mice induces the
recruitment of B-1a cells, neutrophils, and pDCs in the pancreas.
B-1a cells secrete anti-dsDNA IgGs which activate neutrophils that
in turn release DNA-binding CRAMP (cathelicidin related anti-
microbial peptide) in NETs. These immune complexes activate
pDCs through TLR9, leading to local IFN-α production. Using
depleting antibodies, the authors further demonstrated that IFN-α
producing pDCs are essential to initiate T1D in NOD mice (Diana
et al., 2013).
ADAPTIVE PLASMACYTOID DC FUNCTIONS
pDCs FUNCTION AS BONA FIDE Ag PRESENTING CELLS
Accumulating evidence has revealed that pDCs can function as
Ag presenting cells (APCs). In steady-state, pDCs can be easily
detected in the blood, the thymus, and all SLOs (Bendriss-Vermare
et al., 2001; Nakano et al., 2001; Summers et al., 2001; Asselin-
Paturel et al., 2003; Seth et al., 2011). Upon inflammation, pDCs
are recruited on a massive scale to infected or inflamed tissues,
as well as to associated dLNs, and, importantly, in the LN T cell
area, supporting a role for pDCs in activating naïve T cells (Cella
et al., 1999; Krug et al., 2002; Vanbervliet et al., 2003; Irla et al.,
2010). In vitro, pDCs exhibit the ability to capture, process, and
present Ags through MHCI and MHCII molecules (Villadangos
and Young, 2008; Tel et al., 2012). Steady-state pDCs were mainly
described to be tolerogenic. Moreover, following TLR activation,
pDCs upregulate MHCII and costimulatory molecules, which
allow the direct modulation of the adaptive immune response.
However, distinct mechanisms regulate Ag capture and processing
in cDCs and pDCs, as well as resulting T cell outcome, suggesting
complementary and, for the most part, non-overlapping functions
of these two DC subsets.
Intracellularly Ag derived peptides either expressed by the cell
itself (Krug et al., 2003; Young et al., 2008) or derived from
intracellular-virus (Fonteneau et al., 2003; Salio et al., 2004;
Schlecht et al., 2004; McGill et al., 2008; Young et al., 2008) are
efficiently presented by pDCs through MHCI. Whether pDCs can
phagocytose bacteria is still unclear (Villadangos andYoung,2008),
while they have been shown to endocytose virions and exoge-
nous proteins. pDCs express various endocytic receptors: Siglec-H
(Zhang et al., 2006); the tetherin BST-2 (CD317) (Neil et al.,
2008; Viswanathan et al., 2011); DCIR, which mediates clathrin-
dependent endocytosis (Meyer-Wentrup et al., 2008); FcgRII
(CD32), which allows the uptake of opsonized-Ags (Benitez-Ribas
et al., 2006; Bjorck et al., 2008); and, specific to human pDCs,
BDCA-2 which allows Ag delivery in the Ag processing com-
partment (Dzionek et al., 2001). Other receptors, such as ILT-7
(Cao et al., 2006) or NKp44 (Brown et al., 2004) may medi-
ate endocytosis by pDCs, although this hypothesis needs further
experimental confirmation (Villadangos and Young, 2008). Inter-
estingly, ligation of these endocytic receptors potently suppresses
IFN-I production by pDCs after TLR9 triggering (Dzionek et al.,
2001; Blasius et al., 2004; Cao et al., 2007; Meyer-Wentrup et al.,
2008). Finally, pDCs also acquire Ags from exosomes or apoptotic
bodies (Hoeffel et al., 2007; Bastos-Amador et al., 2012).
Recent data suggests that mouse and human pDCs efficiently
cross-present exogenous Ags to CD8+ T cells. In vitro, TLR-
activated pDCs capture, process, and cross-present exogenous
proteins to CD8+ T cells to induce proliferation, IFN-γ pro-
duction, and cytolytic activity (Mouries et al., 2008; Kool et al.,
2011). Accordingly, in vivo OVA delivery to CpG-activated pDCs
via Siglec-H induces the generation of Ag-specific CD8+ T cells
(Zhang et al., 2006), although T cell effector functions were not
investigated in this study. More recently, it was shown that pDC-
depleted Siglec-H-DTR mice immunized with OVA protein in the
presence of TLR ligands exhibit impaired OVA-specific CD8+ T
cell proliferation. Furthermore, the generation of MHC-I-OVA
tetramer+ CD44hi CD8+ T cells, as well as OVA-specific effector
CTL functions, are impaired after pDC depletion (Takagi et al.,
2011). However, this study cannot exclude that decreased CD8+ T
cell activation and differentiation observed following pDC deple-
tion does not reflect the abrogation of pDC cross-presenting
functions, rather than simply the absence of pDC-mediated licens-
ing of cDCs (Yoneyama et al., 2005). Accordingly, the depletion
of cDCs in mice further co-immunized with OVA protein and
CpG completely abrogates OVA-specific CD8+ T cell responses,
suggesting that pDCs do not cross-present exogenous proteins to
CD8+ T cells (Sapoznikov et al., 2007). Thus, the ability of murine
pDCs to cross-present Ags to CD8+ T cells remains controver-
sial. In humans however, it is accepted that blood pDCs efficiently
cross-present viral Ags and initiate Ag-specific antiviral CD8+ T
cell responses after being exposed to either influenza virus (Di Puc-
chio et al., 2008) or HIV-1 infected apoptotic cells (Hoeffel et al.,
2007; Lui et al., 2009). The ability of pDCs to cross-present viral
Ags does not seem to require IFN-I production but this function is
strongly enhanced after TLR activation with synthetic compounds
or influenza virus infection (Hoeffel et al., 2007).
Although some studies cited above suggested that the efficiency
of Ag cross-presentation by pDCs to CD8+ T cells was compara-
ble to that of cDCs, pDCs appear to be much less potent APCs
compared to cDCs in stimulating CD4+ T cells. For instance,
both in vitro and in vivo, CpG-activated pDCs were found not
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to be as efficient as cDCs at presenting exogenous Ag through
MHCII to CD4+ T cells (Young et al., 2008; Kool et al., 2011).
One possible explanation is that mouse cDCs and pDCs exhibit
major differences in their Ag presentation machinery. Notably,
MHCII molecules are differentially regulated in pDCs and cDCs.
MHCII expression is regulated by the class II master transactiva-
tor gene CIITA, itself expressed under the control of distinct cell
specific promoters (Reith et al., 2005). In particular, pDCs rely
strictly on the B cell promoter pIII, whereas macrophages and
cDCs depend on pI (LeibundGut-Landmann et al., 2004). In con-
trast to cDCs, activated pDCs fail to shut down MHCII synthesis
(LeibundGut-Landmann et al., 2004) and turnover (Young et al.,
2008), thereby allowing continued Ag presentation after activation.
These features may indeed render pDCs better equipped for the
continuous presentation of Ags, and allow them to present newly
formed MHCII-peptide complexes even after activation (Sadaka
et al., 2009), a feature with obvious advantages at sites of infection
(Villadangos and Young, 2008). On the other hand, since pDCs
lack the ability to accumulate long-lived MHCII-peptide com-
plexes generated shortly after activation, it may also render these
cells less efficient compared to cDCs at promoting effector CD4+
T cell responses, due to the low the exposure time of the peptide
on cell surface.
IMPACT ON T HELPER FUNCTIONS
As discussed above, activated pDCs present Ags to naïve CD4+
T cells and thus directly contribute to T cell responses as
APCs. In addition, pDCs can also indirectly impact T cells by
producing inflammatory cytokines. As most studies eliminate
pDCs genetically (Swiecki et al., 2010; Takagi et al., 2011) or
through depleting mAbs (Bailey-Bucktrout et al., 2008; Jong-
bloed et al., 2009), it has been difficult so far to decipher the
relative contribution of innate and adaptive pDC functions. How-
ever, accumulating evidence, mainly supported by in vitro studies,
in vivo Ag targeting and abrogation of MHCII expression on pDCs,
suggest a direct role of pDCs in impacting T cell responses. It is
largely accepted that steady-state cDCs constantly present self-
and non-self-Ags in a fashion that promotes T cell tolerance. Con-
versely, signals derived from pathogens or tissue damage generally
boost cDC maturation, which promotes their capacity to induce
effector T cell responses (Steinman, 2007). For pDCs however,
their ability to promote either tolerance or immunity seems not to
rely entirely on their activation state. Indeed, whereas immature
pDCs exclusively promote tolerance, activated pDCs, depending
on the anatomical localization and the cytokine milieu, may have
both immunogenic and tolerogenic functions, although the exact
nature of these functions remains to be established.
Immunogenic pDCs
Previous studies performed in vitro showed that both human
and mouse activated pDCs, given an antigenic peptide together
with appropriate activating signals, activate naïve CD4+ T cells,
and promote Th1 differentiation (Cella et al., 2000; Krug et al.,
2001; Boonstra et al., 2003). In mice devoid of cDCs, CpG-treated
LN pDCs promote Th1 development and memory differentiation
in vivo (Sapoznikov et al., 2007). Similarly, Ag-specific deliv-
ery to TLR-activated pDCs via BST-2 induces Ag-specific Th1
development in vivo, as demonstrated by the production of IFN-
γ by CD4+ T cells and subsequent immunoglobulin production
(Loschko et al., 2011b) (Figure 1). pDCs have also been shown to
induce Th17 responses in different experimental models. Human
TLR7-triggered pDCs promote Th17 differentiation from either
naïve or memory CD4+ T cells (Yu et al., 2010). In patients with
GVHD, increased pDCs and Th17 cell numbers in the intestinal
mucosa correlate with disease severity, suggesting a role of pDCs
in driving Th17 responses during disease (Bossard et al., 2012).
Furthermore, in tumor bearing mice, pDCs activation through
CpG correlates with an increase of tumor-specific Th17 cells and
an inhibition of the tumor growth (Xu et al., 2012) (Figure 1).
The ability of pDCs to promote Th17 differentiation seems to
be enhanced in the presence of TGF-β. Indeed, the transfer of
TGF-β treated pDCs to collagen-induced arthritic mice leads to
increased Th17 responses in LNs leading to increased disease sever-
ity (Bonnefoy et al., 2011). In EAE, anti-PDCA1 mediated pDC
depletion resulted in impaired encephalitogenic Th17 responses
significantly reducing early clinical scores (Isaksson et al., 2009).
Moreover, pDCs may be able to convert Tregs into Th17 cells.
Indeed, in rats, Foxp3+ T cells start to produce IL-17 when acti-
vated by mature pDCs (Gautreau et al., 2011). Using genetically
modified mice selectively lacking MHCII expression by pDCs
(LeibundGut-Landmann et al., 2004), we have found that CpG-
activated pDCs function as APCs to induce Th17 responses in vivo
(Guery et al., manuscript in preparation) (Figure 1). Our unpub-
lished data further suggest that the ability of activated pDCs to
promote Th17 cells may be used as a vaccination strategy against
tumors.
Tolerogenic pDCs
Plasmacytoid DCs have also been demonstrated to be involved
in the induction of central and peripheral tolerance. It has been
suggested that the function of pDCs within the thymus, as in
other tissues, might simply be to protect the tissue from viral
infections (Wu and Shortman, 2005). However, it was recently
suggested that recirculating pDCs might present self-Ags in the
thymus and contribute to the inactivation, or deletion, of autore-
active T cells. pDCs were detected in human thymus, colocalize
with Foxp3+ Tregs, and, when activated with CD40L plus IL-3, effi-
ciently promote the development of Foxp3+ natural Tregs (nTregs)
from autologous thymocytes (Martin-Gayo et al., 2010). Similarly,
human thymic pDCs activated with CpG and TSLP induce nTreg
generation (Hanabuchi et al., 2010). In these two studies, Tregs
generated by pDCs produce more IL-10 and less TGF-β compared
to nTregs primed by cDCs under the same conditions, suggesting
a complementary effect of the two DC subsets in the development
of central tolerance. However, whether pDCs actually promote
thymocyte differentiation into nTreg in vivo remains to be firmly
demonstrated. In contrast to human pDCs, murine thymic pDCs
do not efficiently induce Treg differentiation from thymocytes
in vitro (Proietto et al., 2009). In vivo, a recent study illustrated the
importance of CCR9 in targeting peripheral immature pDCs to the
thymus. This indicates a role for pDCs in presenting extrathymi-
cally acquired Ags to further induce the deletion of Ag-specific
CD4+ thymocytes (Hadeiba et al., 2012). No role for pDCs in the
generation of nTregs was observed in this study, suggesting that
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FIGURE 1 | Activated pDCs induce dual tolerogenic and immunogenicT cell responses.The most relevant in vivo experimental animal systems are
represented in this figure.
mouse pDCs are intrinsically inefficient at inducing Tregs in the
thymic environment in vivo.
Although it was suggested that pDCs are poor presenters of
Ag in the absence of microbial stimulation (Colonna et al., 2004),
immature pDCs promote T cell anergy, T cell deletion, as well
as Treg differentiation. In humans, freshly isolated pDCs induce
anergy in human CD4+ T cell clones, but it is reversed upon
the addition of exogenous IL-2 (Kuwana, 2002). In mice, pDCs
prevent oral T cell priming and are responsible for systemic tol-
erance to dietary Ags including proteins and haptens (Goubier
et al., 2008). Indeed, pDC depletion induces hypersensitivity and
CD8+ T cell responses toward oral Ags. In contrast, the trans-
fer of Ag-loaded immature pDCs in naive mice suppresses both
Ag-specific CD4+ and CD8+ T cell responses by inducing either
anergy or deletion, suggesting that oral tolerance relies on Ag pre-
sentation by pDCs (Goubier et al., 2008) (Figure 2). Immature
pDCs expressing CCR9 were defined as inducers of Foxp3+ Tregs
that suppress Ag-specific immune response in a GVHD model.
Importantly, transferred CCR9+ pDCs efficiently suppressed allo-
genic GVDH (Hadeiba et al., 2008). pDCs were also identified
as phagocytic APCs essential for tolerance to vascularized car-
diac allografts (Ochando et al., 2006) (Figure 2). In this model,
alloantigen-presenting pDCs home to the LNs under tolerogenic
conditions, where they mediate alloantigen-specific Treg develop-
ment and allograft tolerance. In an other model of cardiac allograft
transplantation, the absence of pDCs in LNs from CCR7−/− mice
impairs Treg induction, and results in graft rejection, whereas
pDC transfer restores both Treg frequencies and tolerance to
the cardiac allograft (Liu et al., 2011) (Figure 2). In rats, pDCs
also induce tolerance to allografts by inhibiting CD4+ T cells
either directly through an indoleamine 2,3-dioxygenase (IDO)-
dependent mechanism, or indirectly through the induction of
CD8+ Tregs (Li et al., 2010) (Figure 2). Furthermore, pDC deple-
tion in mice induces classical features of asthma after inhalation
of an inert Ag, including IgE sensitization, airway eosinophilia,
goblet cell hyperplasia, and Th2 cytokine production. In contrast,
the adoptive transfer of pDCs before sensitization prevents asthma,
possibly through the induction of Tregs (de Heer et al., 2004). Using
Siglec-H inducible deficient mice,a recent study nicely showed that
Siglec-H controls the ability of steady-state pDCs to induce the
conversion of naïve CD4+ T cells in inducible Tregs (iTregs) in vivo
(Takagi et al., 2011). In the contexts of tumors, the microenviron-
ment maintains a resting pDC phenotype, characterized by low
expression of costimulatory molecules and low IFN-I production
(Hartmann et al., 2003; Conrad et al., 2012; Sisirak et al., 2012).
Consequently, pDCs induce mainly tolerogenic tumor CD4+ T
cell responses, through IDO-dependent Treg generation (Sharma
et al., 2007) (Figure 2). Accordingly, IDO inhibition in pDCs pro-
motes the conversion of Tregs into Th17 cells that efficiently inhibit
tumor growth (Sharma et al., 2009). ICOS-L expression by pDCs
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FIGURE 2 | Immature pDCs induce tolergenicT cell responses.The most relevant in vivo experimental animal systems are represented in this figure.
in the tumor context has also been implicated in their ability to
generate Tregs (Conrad et al., 2012; Faget et al., 2012) (Figure 2).
Activated pDCs were demonstrated to favor Treg development.
Treg induction has been correlated with low peptide-MHCII den-
sities on APCs (Kang et al., 2007; Turner et al., 2009). Thus, the
ability of activated pDCs to induce Tregs might be explained by
the fact that they do not stabilize peptide-MHCII complexes at
their cell surface, and, thus, provide a weak TCR engagement pro-
moting Treg development. In humans, TLR-activated pDCs induce
the development of IL-10 producing Tregs in an ICOS dependent
manner (Ito et al., 2007; Ogata et al., 2013). Furthermore, HIV-
stimulated IDO expressing pDCs induce the differentiation of
naive CD4+ T cells into Tregs (Manches et al., 2008). CpG-activated
human pDCs can also promote Treg differentiation (Moseman
et al., 2004), possibly in an IDO-dependent fashion (Chen et al.,
2008). Finally, TLR-activated rat pDCs induce Treg proliferation
in vitro (Ouabed et al., 2008).
The severity of several autoimmune diseases has been demon-
strated to be regulated by pDCs. In rheumatoid arthritis, mature
pDCs from patients express high levels of IDO and are necessary
for the differentiation of allogeneic naïve CD4+ CD25− T cells
into IL-10 producing Treg (Tr1) cells (Kavousanaki et al., 2010).
Moreover, in an in vivo mouse model of arthritis, pDC depletion
correlates with enhanced articular pathology and increased T and
B cell autoimmune responses to type II collagen (Jongbloed et al.,
2009). In lupus, low dose Ag therapy induces the production of
TGF-β by pDCs and dampens their ability to respond to TLR
stimulation. The transfer of these tolerogenic pDCs promotes
Treg expansion while simultaneously suppressing inflammatory
Th17 infiltrating the kidney of lupus-prone mice (Kang et al.,
2007). Ag targeting in pDCs has also been shown to inhibit T
helper cell dependent autoimmunity. In EAE, Siglec-H mediated
MOG35–55 delivery to pDCs dampens EAE, by inducing MOG-
specific CD4+ T cell hyporesponsiveness resulting in the impaired
induction of Th1 and Th17 cells, without promoting Treg dif-
ferentiation (Loschko et al., 2011a) (Figure 1). Using a genetic
mouse model in which MHCII is specifically abrogated in pDCs,
we also identified a tolerogenic role for Ag presenting pDC func-
tions during EAE. We demonstrated that pDCs, by presenting
myelin Ags to naïve CD4+ T cells, induce the expansion of nTregs.
As a consequence, mice carrying a selective abrogation of MHCII
on pDCs exhibit impaired nTreg expansion, increased encephali-
togenic Th1 and Th17 responses and exacerbated EAE (Irla et al.,
2010) (Figure 1).
As discussed before, pDCs contribute to the pathology of T1D
through the production of IFN-I. However, pDCs are also impli-
cated in the inhibition of diabetogenic T cells during infections.
In RIP-LCMV mice, OX40-OX40L dependent pDC–iNKT cell
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interactions control viral replication in pancreatic islets of LCMV
infected mice by inducing IFN-I production by pDCs (Diana et al.,
2009). In addition, this pDC–iNKT cooperation has been reported
to promote TGF-β production by pDCs, that in turn, acquire the
ability to convert naive anti-islet CD4+ T cells into Foxp3+ Tregs
in pancreatic dLNs. These Tregs are then recruited in the pancre-
atic islets where they produce TGF-β that inhibits islet-specific
CD8+ T cells and dampens T1D severity (Diana et al., 2011). In
NOD mice, pDC depletion leads to accelerated insulitis and dis-
ease onset, and correlates with a local loss of IDO, suggesting that
during T1D, pDCs may exert IDO-dependent tolerogenic func-
tions by regulating islet-specific CD4+ T cell responses (Saxena
et al., 2007).
In summary, pDCs in SLO were shown to contribute to
T cell tolerance in several experimental systems, regardless
of whether they exhibit a steady-state or activated phenotype
(Figures 1 and 2). Interestingly, tolerogenic pDC functions were
demonstrated to be dependent on IDO in several models. Fur-
thermore, IDO contribution does not seem to rely on a pDC
inflammatory environment. Why and how IDO is involved in
the ability of pDCs to dampen some, but not all, Ag-specific
T cell responses is still a matter of debate. This phenomenon
is more complex due to recent findings demonstrating a sec-
ond function for pDC-derived IDO. Together with the trypto-
phan catalytic activity inhibiting effector T cell function, IDO
has been postulated to act as a signaling protein in response to
TGF-β inducing the conversion of naïve CD4+ T cells into Tregs
(Pallotta et al., 2011). Thus, the relative contribution of the dual
IDO functions needs to be addressed in the different models where
an IDO-dependent inhibition of T cell responses by pDCs has been
described.
CONCLUDING REMARKS
Thus, steady-state pDCs exclusively promote T cell tolerance.
However, the emerging picture of pDC functions during the
development of inflammatory autoimmune disorders is that they
contribute to disease pathogenesis by the production of IFN-I,
while promoting self-Ag-specific CD4+ T cell tolerance though
their ability to present auto-Ag. Altogether, studies show that
innate and adaptive pDC functions may have opposite effects on T
cell tolerance toward self-tissues. Interestingly, the engagement of
endocytic receptors favors Ag presenting pDC functions, while it
dampens their ability to produce IFN-I, suggesting that Ag target-
ing in pDCs would represent an attractive therapeutical strategy
to control autoimmunity and graft rejection.
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